{"prompt": "['Date: June 30, 2020', 'Principal Investigator: James Black', 'Application Number: IRB00075706', 'Clinical Trial Database report:', 'The sponsor-investigator with an applicable study registered with the National Institutes of Health (NIH)', \"National Library of Medicine's (NLM) ClinicalTrials.gov will report results of the study within 12 months\", 'of the trial reaching its completion data regardless of outcomes or if the study is terminated early.', 'Failure to obtain informed consent:', 'The sponsor-investigator will submit a report of the use of a device without first obtaining informed', 'consent. The report will be made to FDA within 5 working days after receipt of the notice of such use.', 'Other reports:', 'The sponsor-investigator will provide accurate, complete, and current information about any aspect', 'of the investigation upon request from the reviewing IRB or FDA.', 'Data and Safety Monitoring', 'This study will have oversight by Sanford Data Safety Monitoring Board (DSMB) consisting of', 'independent scientific and bio-statistical expertise, who are not participating as investigators in the study.', 'Sanford is an integrated healthcare system comprised of hospitals, physicians, and other healthcare', 'providers and facilities located in Sioux Falls, SD. The Sanford DSMB will comprise at least 1 physician', 'experienced in treating the study population and an independent biostatistician (including NAMSA', 'statistical support). The Sanford DSMB will work with the PI to monitor and evaluate the safety of', 'subjects and progress of the study. The board will meet after every 5th patient receiving the investigational', 'device and annually during the follow-up period to review subject data. The board will also meet at', 'unscheduled times according to clinical necessity. The data safety reports reviewed at each meeting will', 'contain enrollment data and all documented adverse events experienced by the participants and treatment', 'outcomes. The focus of the analysis is to determine whether enrollment should continue or be closed and', 'whether the trials should continue as originally designed or require modification/amendment.', 'Definitions', 'Aortic aneurysm enlargement: >5mm as compared to any previous CT measure using orthogonal (i.e.,', 'perpendicular to the centerline) measurements', 'Aortoiliac aneurysm: aneurysm of the abdominal aorta and including one or both of the iliac arteries', 'Aneurysm-related mortality:', 'Death occurring within 30 days or during hospitalization following the index procedure, unless', 'there is evidence of accidental or self-inflicted death;', 'Death occurring within 30 days or during hospitalization following conversion to open repair or a', 'secondary intervention for migration, Type I and III endoleaks, device integrity failure (e.g.,', 'fracture), or patency-related events (i.e., device stenosis or occlusion and embolic events), unless', 'there is evidence of accidental or self-inflicted death;', 'Death occurring within 30 days or during hospitalization for a complication of the aneurysm or a', 'complication associated with the device, such as:', 'aortic rupture', 'fistula formation (e.g., aorto-enteric)', 'embolization', 'malperfusion of organ(s) or limb(s)', 'Version 4.0', 'Page 45 of 54']['Date: June 30, 2020', 'Principal Investigator: James Black', 'Application Number: IRB00075706', 'Arterial fistula formation: formation of an abnormal connection or passageway between an artery and', 'adjacent structures', 'Conversion to Open, Early: any open repair within 30 days of the index procedure involving the', 'vasculature in the abdomen and/or pelvis.', 'Conversion to Open, Late: any open surgical repair involving stentgraft removal after 30days post index', 'procedure', 'Chronic Obstructive Pulmonary Disease (COPD): forced expiratory volume (FEV1) < 1.0 liter or', 'receiving home oxygen', 'Crawford Type IV TAAA: aneurysmal dilatation originating within 5cm of the celiac artery', 'Disabling stroke: Modified Rankin Score MRS >2', 'Distal landing zone: aortic fixation site furthest from the heart', 'Embolization: dislodging of an upstream particle that travels downstream causing blockage of free flow', 'further downstream. Embolization could result in malperfusion', 'Embolus: blood clot that forms at one location (presumably from the aneurysmal sac, aortic neck, or', 'adjacent vessels) and is dislodged to another location resulting in ischemic changes', 'Emergent: an aneurysm requiring immediate treatment', 'Endoleak:', 'Type I: leak occurring at the proximal or distal fixation site, including leakage around fenestrations', 'Type Ia: leak occurring at the proximal fixation zone of the stent-graft', 'Type Ib: leak occurring at the distal fixation zone of the stent graft', 'Type Ic: leak occurring at the distal fixation zone of the covered stents in the visceral vessels', 'incorporated by the fenestrations', 'Type II: leak caused by retrograde flow from patent lumbar or inferior mesenteric arteries', 'Type IIIa: leak caused by a defect in the graft fabric', 'Type IIIb: leak caused by inadequate seal between modular graft components', 'Type IV: leak caused by graft fabric porosity, often resulting in a generalized blush of contrast', 'within the aneurysm sac', 'Type V: aneurysm enlargement without visualized leak', 'Endoleak, Early: any endoleak observed within 30 days after device deployment', 'Version 4.0', 'Page 46 of 54']\n\n###\n\n", "completion": "END"}